(Check
One):
|
[X]
Form 10-K or Form 10-KSB [ ] Form
11-K [ ] Form 20-F [ ] Form
10-Q or Form 10-QSB [ ] Form
10-D [ ] Form N-SAR [ ] Form
N-CSR
|
|
For
Period Ended: December 31,
2007
|
||
[ ] Transition Report on Form 10-K or Form
10-KSB
[ ]
Transition Report on Form 20-F
[ ]
Transition Report on Form 11-K
[ ]
Transition Report on Form 10-Q or Form 10-QSB
[ ]
Transition Report on Form N-SAR
|
||
For the Transmition Period Ended: ____________________________________________________________________________ |
BIOSPECIFICS TECHNOLOGIES CORP. |
35 Wilbur Street |
Lynbrook, NY 11563 |
|
(a)
The reasons described in reasonable detail in Part III of this form could
not be eliminated without unreasonable effort or
expense;
|
[X]
|
(b) The
subject annual report, semi-annual report, transition report on Form 10-K,
Form 10-KSB, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following
the prescribed due date; or the subject quarterly report or transition
report on Form 10-Q or Form 10-QSB, or subject distribution report on Form
10-D, or portion thereof, will be filed on or before the fifth calendar
day following the prescribed due date;
and
|
|
(c) The
accountant’s statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
(1)
|
Name
and telephone number of person to contact in regard to this
notification
|
Thomas
L. Wegman
(President)
|
516-593-7000
|
(Name)
|
(Telephone
Number, including Area Code)
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that
the registrant was required to file such report(s) been filed? If the
answer is no, identify report(s).
|
(3)
|
Is
it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof?
|
|
If
so: attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why
a reasonable estimate of the results cannot be
made.
|
BIOSPECIFICS TECHNOLOGIES
CORP.
|
||
(Name
of Registrant as Specified in Charter)
|
Date: March 31,
2008
|
By:
|
/s/ Thomas L.
Wegman
|
|
|
Name:
Thomas L. Wegman
Title: President
|